GlobeNewsWire · 13 Aug 2026neutral
Mineralys Therapeutics granted an inducement stock option award covering 135,000 shares and an inducement restricted stock unit award covering 102,400 shares to its newly appointed Chief Medical Officer, Dr. Terry Ferguson, on August 10, 2026. The award was approved by a majority of the independent directors of the Company's Board of Directors under Nasdaq Listing Rule 5635(c)(4).
Why it matters — The inducement award provides information on executive compensation for a newly hired senior leader, which MLYS watchers may consider when evaluating the company's leadership incentives and governance practices.
Seeking Alpha · 12 Aug 2026neutral
Seeking Alpha published the transcript of Mineralys Therapeutics' Q2 2026 earnings call, covering the company's second-quarter results and management discussion. The item is a record of the earnings call proceedings.
Why it matters — A MLYS watcher would care because the transcript provides direct, unedited access to management commentary and operational detail from the company's latest earnings call.
MarketBeat · 11 Aug 2026neutral
Mineralys Therapeutics reported a wider second-quarter loss, driven largely by a $200 million upfront payment related to its amended agreement with Tanabe Pharma Corp. The company said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date.
Why it matters — MLYS watchers would care because the wider loss reflects a major strategic deal with Tanabe Pharma while the company advances lorundrostat toward its December 22 PDUFA target date and commercial launch preparations.
GlobeNewsWire · 11 Aug 2026positive
Mineralys Therapeutics reported its second quarter 2026 financial results, provided a corporate update noting a PDUFA target date of December 22, 2026 for lorundrostat, appointed Dr. Terry Ferguson as Chief Medical Officer, and completed strategic financing initiatives including the repurchase of the Tanabe royalty obligation.
Why it matters — A MLYS watcher would care because the company is progressing toward a key regulatory decision for its lead candidate lorundrostat, strengthening its commercial readiness and financial position ahead of a potential December 2026 launch.
GlobeNewsWire · 27 July 2026neutral
Mineralys Therapeutics granted inducement stock option and restricted stock unit awards totaling 42,800 shares and 32,100 shares, respectively, to two new non-executive employees on July 17 and July 20, 2026. The inducement awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
Why it matters — The grants signal that Mineralys is hiring new non-executive talent, though the awards are standard inducements for new employees and do not reflect company performance or financial outlook.
